You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Drug Delivery Technology for Stem Cell-Based TMJ Regeneration

    SBC: WNT SCIENTIFIC LLC            Topic: NIDCR

    Summary The temporomandibular jointTMJis a complex joint system critical for dentalocclusionmasticationrespiration and speechThe TMJ is comprised of a network of musclesligamentsand a fibrocartilaginous disc and condyleTMJ trauma and degenerative diseasesincluding TMJ osteoarthritisOAare debilitating and compromise quality of lifeTMJ diseasesafflict overmillion Americans at an annual cost of$billi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence

    SBC: KannaLife Sciences Inc.            Topic: NIDA

    Chemotherapy induced peripheral neuropathyCIPNcan be a chronicseverely debilitating consequence of cancer therapy for which there are no effective management strategiesMoreoverupwards ofof CIPN patients reported using prescription opioids for pain management despite the fact that there is only weak evidence that long term continuation of opioids provides clinically significant pain relief in these ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of mitochondrial disease mouse models

    SBC: B-MoGen Biotechnologies Inc            Topic: OD

    Project Abstract Mitochondria are double membrane bound organelles that are found in all eukaryotic cells and carry a specialized circularkb genomeThere is a group of devastating human genetic diseases caused by inherited or spontaneous mutation of genes encoded within the mitochondrial genomeThese diseases can cause a wide array of medical problems from subtle muscular weakness to extreme neuromu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Noninvasive System for Detection of Sleep Apnea in Animals

    SBC: NEOGENE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Optimized Endectocide-treated Bird Feed Formulations for West Nile Virus Control

    SBC: TDA RESEARCH, INC.            Topic: NIAID

    Project Summary Abstract Development of Optimized Endectocide treated Bird Feed Formulations for West Nile Virus Control STTR Phase I Application PIs Brady Clapsaddle TDA Research Inc Dr Brian Foy Colorado State University West Nile Virus WNV is the leading cause of domestically acquired arboviral disease in the United States resulting in significant disease and death every year in both ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Non-alcoholic steatohepatitis (NASH) is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates. NASH is frequently associated with other common metabolic abnormalities, such as insulin resistance and visceral obesity. Liver transplantation is curren ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Device for Treatment of Congenital Diaphragmatic Hernia

    SBC: H-CUBED            Topic: NHLBI

    DESCRIPTION provided by applicant Congenital diaphragmatic hernia CDH affects in newborns CDH is a disorder in which part of the diaphragm fails to form allowing abdominal organs to migrate into the chest resulting in lung hypoplasia underdevelopment in affected infants Although great strides have been made in the management of this disease significant morbidity and mortality p ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)

    SBC: CENTERLINE BIOMEDICAL INC            Topic: NHLBI

    Project Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government